Entelos is providing biosimulation services to J&J, compensated in part through the grant of this option, and will develop a new PhysioLab platform to support its internal development of the phase I compound.
James Karis, president and CEO of Entelos, said: “Acquiring the option to develop selective progesterone receptor modulators reflects our strategy to leverage our predictive disease simulation systems into drug ownership rights.”
Entelos' PhysioLab predictive biosimulation computer models are used to validate novel drug targets, select and develop compounds, assess safety and optimize clinical trials.